ICH Study Center GmbH & Co. KG — Clinical Trial Site

17 Registered trials

2 Currently recruiting

Organisation

ICH Study Center GmbH & Co. KG

Location

Hamburg, Germany

Identifier

ORG-100043598

Address

Grindelallee 35, Rotherbaum, 20146, Germany

Departments

ICH (Infektionsmedizinisches Centrum Hamburg)
ICH MVZ Grindel
ICH Study Center
ICH Study Center GmbH & Co. KG
Infectious diseases
N/A
NA
Rheumatology
Rotherbaum

Clinical trials at this site (17)

Search interface

A clinical study of people with HIV‐1 who switch their treatment to a combination of doravirine and islatravir Not authorised

2022-502079-49-00 HIV-1 infection 5
A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi… Not authorised

2022-502099-22-00 HIV-1 Infection 5
A clinical study of people with HIV-1 who received prior treatment combination of doravirine and islatravir Not authorised

2022-502126-40-00 HIV-1 infection 5
Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed Pending

2024-511054-50-00 HIV-1 Infection 10
Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Recruiting

2025-522015-42-00 Chronic Hepatitis D Infection 10 2026-02-26
Safety and immunologic response of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis Recruiting

2024-512881-32-00 Psoriasis vulgaris and/or psoriatric arthritis 6 2023-11-22
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (INNOVATE Study) Ended

2025-521918-26-00 HIV Infections 4 2026-02-11
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppres… Ended

2024-514046-37-00 HIV-1 Infection 5 2025-01-16
A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi… Ended

2022-502099-22-01 HIV-1 Infection 5 2024-04-29
A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug … Ended

2023-504993-40-00 Human immunodeficiency virus (HIV) 5 2024-02-14
Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended

2023-506867-33-01 Chronic Hepatitis B 4 2022-01-25
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended

2024-512505-66-00 HIV-1 Infection 10 2025-03-03
Proof of concept treatment study of orally administered VH4004280 or VH4011499 in HIV-1 infected adults Ended

2023-505350-18-00 HIV Infections 4 2023-12-15
A study on the reactogenicity, safety, immune response, and efficacy of a targeted immunotherapy against HSV in healthy participants aged 18… Ended

2024-510571-37-00 Herpes Simplex 7 2023-12-06
Safety and efficacy of GSK Neisseria gonorrhoeae GMMA (NgG) investigational vaccine when administered to healthy adults 18 to 50 years of ag… Ended

2022-500883-37-00 This FTiH-PoC study aims to provide an early evaluation 7 2023-10-02
Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 2) Ended

2023-504238-23-00 Hepatitis B, Chronic 5 2023-01-17
The Late Presenter Treatment Optimisation Study (LAPTOP) Ended

2023-505167-36-00 Patients who present late on during their acquisition o 5 2019-08-05